Q3 2019

Filed Nov 8, 2019 · 10-Q · 39 days after period end · 0000886163-19-000199

Q3 2019 · 10-Q

Revenue

$24.81M

−45.7% vs Q3 2018

Net Income

-$15.25M

N/M vs Q3 2018

EPS Diluted

-$0.81

N/M vs Q3 2018

Operating Income-$5,158,000N/M

Operating Cash Flow

Same quarter

Metric	Q3 2019	Q3 2018	Q3 2017	Q3 2016
Revenue	$24.81M	$45.66M	$45.66M	$21.62M
Net Income	-$15.25M	$67.36M	$67.36M	$1.05M
EPS Diluted	-$0.81	$2.80	$2.80	$0.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR